Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Savient Pharmaceuticals (United States)
Alternate names:
Bio-Technology General Corp,
Savient Pharmaceuticals,
Savient Pharmaceuticals, Inc.
ROR:
02yrbkt92
OpenAlex ID:
I4405280449
Works
39
Awards
13
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
2007
·
Kenneth W. Lyles
, Cathleen S. Colón-Emeric
, et al.
·
New England Journal of Medicine
·
2,171
PDF
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
2014
·
Peter E Lipsky
, Leonard H Calabrese
, et al.
·
Arthritis Research & Therapy
·
282
PDF
Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase
2003
·
Jonathan M. Davis
, Richard B. Parad
, et al.
·
PEDIATRICS
·
274
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
2007
·
John S. Sundy
, Nancy J. Ganson
, et al.
·
Arthritis & Rheumatism
·
237
The Effects of TLR Activation on T-Cell Development and Differentiation
2012
·
Bo Jin
, Tao Sun
, et al.
·
Clinical and Developmental Immunology
·
224
PDF
Quality of Life and Disability in Patients with Treatment-Failure Gout
2009
·
MICHAEL A. BECKER
, H. RALPH SCHUMACHER
, et al.
·
The Journal of Rheumatology
·
195
PDF
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout: Results of a phase II randomized study
2008
·
John S. Sundy
, Michael A. Becker
, et al.
·
Arthritis & Rheumatism
·
186
Clinical Significance of weight loss in cancer patients: Rationale for the use of anabolic agents in the treatment of cancer-related cachexia
2001
·
Corey J. Langer
, John P. Hoffman
, et al.
·
Nutrition
·
144
Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone
2002
·
Shing-shing Yeh
, Bernadette DeGuzman
, et al.
·
CHEST Journal
·
137
Safety and Pharmacokinetics of Multiple Doses of Recombinant Human CuZn Superoxide Dismutase Administered Intratracheally to Premature Neonates With Respiratory Distress Syndrome
1997
·
Jonathan M. Davis
, Warren N. Rosenfeld
, et al.
·
PEDIATRICS
·
132
Chronic gout: epidemiology, disease progression, treatment and disease burden
2010
·
Richard A. Brook
, Anna Forsythe
, et al.
·
Current Medical Research and Opinion
·
124
Long-term safety of pegloticase in chronic gout refractory to conventional treatment
2012
·
Michael A Becker
, Herbert S B Baraf
, et al.
·
Annals of the Rheumatic Diseases
·
109
PDF
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy
2010
·
N.L. Edwards
, J.S. Sundy
, et al.
·
Journal of Medical Economics
·
100
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
2013
·
Herbert SB Baraf
, Michael A Becker
, et al.
·
Arthritis Research & Therapy
·
94
PDF
Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide
2011
·
Nicola Dalbeth
, Cameron Schauer
, et al.
·
Annals of the Rheumatic Diseases
·
81
Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials
2012
·
VIBEKE STRAND
, DINESH KHANNA
, et al.
·
The Journal of Rheumatology
·
77
PDF
Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy
2011
·
Eric Q. Wu
, Anna Forsythe
, et al.
·
American Journal of Therapeutics
·
74
Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
2014
·
Herbert S. B. Baraf
, Robert A. Yood
, et al.
·
JCR Journal of Clinical Rheumatology
·
67
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
2009
·
for the HORIZON Pivotal Fracture Trial
, R. Eastell
, et al.
·
Osteoporosis International
·
50
PDF
Resolution of gouty tophi after twelve weeks of pegloticase treatment
2008
·
Herbert S. B. Baraf
, Alan K. Matsumoto
, et al.
·
Arthritis & Rheumatism
·
46
The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair
2004
·
Cathleen S. Colón-Emeric
, John Caminis
, et al.
·
Current Medical Research and Opinion
·
44
Long-Term Follow-up of Premature Infants Treated With Prophylactic, Intratracheal Recombinant Human CuZn Superoxide Dismutase
2000
·
Jonathan M Davis
, Susan E Richter
, et al.
·
Journal of Perinatology
·
43
Evaluation of the Effects of Oxandrolone on Malnourished HIV-Positive Pediatric Patients
1999
·
Sarah Fox-Wheeler
, Linda Heller
, et al.
·
PEDIATRICS
·
43
Toward a valid definition of gout flare: Results of consensus exercises using delphi methodology and cognitive mapping
2009
·
W. J. Taylor
, R. Shewchuk
, et al.
·
Arthritis Care & Research
·
39
Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials
2014
·
Robert A Yood
, Faith D Ottery
, et al.
·
BMC Research Notes
·
34
PDF
Show more works
View as search
Works count:
39
Citation count:
5,110
Year
Topic
Type